Literature DB >> 24484236

Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer.

Claire Germain1, Sacha Gnjatic, Fella Tamzalit, Samantha Knockaert, Romain Remark, Jérémy Goc, Alice Lepelley, Etienne Becht, Sandrine Katsahian, Geoffray Bizouard, Pierre Validire, Diane Damotte, Marco Alifano, Pierre Magdeleinat, Isabelle Cremer, Jean-Luc Teillaud, Wolf-Herman Fridman, Catherine Sautès-Fridman, Marie-Caroline Dieu-Nosjean.   

Abstract

RATIONALE: It is now well established that immune responses can take place outside of primary and secondary lymphoid organs. We previously described the presence of tertiary lymphoid structures (TLS) in patients with non-small cell lung cancer (NSCLC) characterized by clusters of mature dendritic cells (DCs) and T cells surrounded by B-cell follicles. We demonstrated that the density of these mature DCs was associated with favorable clinical outcome.
OBJECTIVES: To study the role of follicular B cells in TLS and the potential link with a local humoral immune response in patients with NSCLC.
METHODS: The cellular composition of TLS was investigated by immunohistochemistry. Characterization of B-cell subsets was performed by flow cytometry. A retrospective study was conducted in two independent cohorts of patients. Antibody specificity was analyzed by ELISA.
MEASUREMENTS AND MAIN RESULTS: Consistent with TLS organization, all stages of B-cell differentiation were detectable in most tumors. Germinal center somatic hypermutation and class switch recombination machineries were activated, associated with the generation of plasma cells. Approximately half of the patients showed antibody reactivity against up to 7 out of the 33 tumor antigens tested. A high density of follicular B cells correlated with long-term survival, both in patients with early-stage NSCLC and with advanced-stage NSCLC treated with chemotherapy. The combination of follicular B cell and mature DC densities allowed the identification of patients with the best clinical outcome.
CONCLUSIONS: B-cell density represents a new prognostic biomarker for NSCLC patient survival, and makes the link between TLS and a protective B cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24484236     DOI: 10.1164/rccm.201309-1611OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  250 in total

Review 1.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

Review 2.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma.

Authors:  Erin Schenk; Jennifer Boland; Aaron Mansfield; Marie Christine Aubry; Allan Dietz
Journal:  Med Oncol       Date:  2017-07-15       Impact factor: 3.064

4.  A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases.

Authors:  Anne Montfort; Oliver Pearce; Eleni Maniati; Benjamin G Vincent; Lisa Bixby; Steffen Böhm; Thomas Dowe; Edmund H Wilkes; Probir Chakravarty; Richard Thompson; Joanne Topping; Pedro R Cutillas; Michelle Lockley; Jonathan S Serody; Melania Capasso; Frances R Balkwill
Journal:  Clin Cancer Res       Date:  2016-06-27       Impact factor: 12.531

Review 5.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

Review 6.  Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer.

Authors:  Si-Si Wang; Wei Liu; Dalam Ly; Hao Xu; Limei Qu; Li Zhang
Journal:  Cell Mol Immunol       Date:  2018-04-08       Impact factor: 11.530

7.  Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients.

Authors:  Audrey Hennequin; Valentin Derangère; Romain Boidot; Lionel Apetoh; Julie Vincent; David Orry; Jean Fraisse; Sylvain Causeret; François Martin; Laurent Arnould; Françoise Beltjens; François Ghiringhelli; Sylvain Ladoire
Journal:  Oncoimmunology       Date:  2015-06-03       Impact factor: 8.110

8.  B cells for cancer immunotherapy.

Authors:  Jiusheng Deng; Jacques Galipeau
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

9.  Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Authors:  Soizic Garaud; Laurence Buisseret; Cinzia Solinas; Chunyan Gu-Trantien; Alexandre de Wind; Gert Van den Eynden; Celine Naveaux; Jean-Nicolas Lodewyckx; Anaïs Boisson; Hughes Duvillier; Ligia Craciun; Lieveke Ameye; Isabelle Veys; Marianne Paesmans; Denis Larsimont; Martine Piccart-Gebhart; Karen Willard-Gallo
Journal:  JCI Insight       Date:  2019-08-13

10.  Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.

Authors:  Véronique M Braud; Jérôme Biton; Etienne Becht; Samantha Knockaert; Audrey Mansuet-Lupo; Estelle Cosson; Diane Damotte; Marco Alifano; Pierre Validire; Fabienne Anjuère; Isabelle Cremer; Nicolas Girard; Dominique Gossot; Agathe Seguin-Givelet; Marie-Caroline Dieu-Nosjean; Claire Germain
Journal:  Oncoimmunology       Date:  2018-01-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.